SCHEMBL14949352

SCHEMBL14949352

Cc1cccc(Nc2nnc(-c3cccc(Oc4cc(N)nc(C)n4)c3)[nH]2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.35
KIT P10721 1/20 0.35
PDGFRA P16234 1/20 0.35
CDK11B P21127 1/20 0.35
FLT3 P36888 1/20 0.35
CDKL2 Q92772 1/20 0.35
MAPT P10636 6/20 0.35
TP53 P04637 5/20 0.35
CDK8 P49336 1/20 0.35
NFKB1 P19838 1/20 0.34
ADORA2A P29274 1/20 0.33
MAP4K4 O95819 1/20 0.33
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
SRC P12931 1/20 0.32
SLC2A1 P11166 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
ABL2 P42684 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949316 0.92 RAB9A (0.36) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949258 0.91 PDGFRB (0.43) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949341 0.90 MEN1 (0.37) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949345 0.89 NPC1 (0.34) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336569 0.89 PDGFRB (0.47) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949376 0.87 PDGFRB (0.34) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949356 0.87 CDK8 (0.34) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949362 0.86 PDGFRB (0.40) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949388 0.86 KIT (0.37) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949332 0.86 RAB9A (0.38) MAPTTP53CDK8ADORA2AMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.